Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
Objective To estimate the cost-effectiveness of omalizumab compared with standard of care in the treatment and control of severe persistent asthma, using the outcomes from the Portuguese subpopulation of the eXpeRience registry.Methods This was a pragmatic cost-effectiveness analysis based on real w...
Saved in:
| Main Authors: | A. Arrobas, M.P. Barbosa, S. Rabiais, B. Vandewalle, J. Félix |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2021-03-01
|
| Series: | Pulmonology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1016/j.pulmoe.2020.03.001 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
by: V. S. Krysanova, et al.
Published: (2021-08-01) -
Clinical Efficacy and Safety of Combined House Dust mite Subcutaneous Immunotherapy and Omalizumab in Five Cases of Allergic Rhinitis and Asthma
by: P.C. Kathuria, et al.
Published: (2021-07-01) -
Steroid-Sparing Effect of Omalizumab in Stage IV (Corticosteroid Dependent) Allergic Bronchopulmonary Aspergillosis
by: P. C. Kathuria, et al.
Published: (2020-04-01) -
Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China
by: Yueyang Huang, et al.
Published: (2025-07-01) -
Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
by: Petek Üstün, et al.
Published: (2025-07-01)